RecruitingNot ApplicableNCT06469307
Driving Inclusivity, Validity, and Equity in Research Through Strategic Engagement (DIVERSE)
Sponsor
Dana-Farber Cancer Institute
Enrollment
40 participants
Start Date
Dec 9, 2024
Study Type
INTERVENTIONAL
Conditions
Summary
The purpose of this research study is to enhance inclusion and diversity in clinical trial enrollment by training participants to perform and provide feedback through a community-based protocol review process, called DIVERSE.
Eligibility
Min Age: 18 Years
Inclusion Criteria8
- Age 18 or older
- English speaking
- Ability to understand and willingness to provide oral consent
- DFCI patient who are in remission from a blood cancer \>1 year will be preferred.
- Age 18 older
- English Speaking
- Site or Principal investigator
- Not a member of the research team
Exclusion Criteria6
- Adults unable to consent
- Individuals who are not yet adults (infants, children, teenagers \<18 years old)
- Prisoners.
- Unwilling/unable to agree to maintaining the confidentiality of reviews and clinical trial materials, as outlined in Section 9.1
- Note 1: Patients and non-patient community members who are pregnant are eligible. This is a non-interventional study that meets the definition of minimal risk and poses no greater risk to pregnant individuals or fetuses. Pregnancy status will not be assessed.
- Note 2: English fluency is necessary as protocols being reviewed are written in English and cannot be feasibly translated to other languages within the time period necessary to complete timely reviews.
Interventions
OTHERDIVERSE Review Process
A participant and community-based review system for clinical research protocols that elicits and collects feedback on investigator-initiated protocol reviews.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06469307
Related Trials
Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies
NCT069040661 location
CIML NK Cells With Venetoclax for AML
NCT061528092 locations
Cognitive Aftereffects of Neurotoxicity in Children and Young Adults With Relapsed/Refractory Hematologic Malignancies Who Receive CAR T-cell Therapy
NCT052379863 locations
Clinical Study on the Safety and Efficacy of BiTE-EV in Relapsed/Refractory Acute B-Cell Leukemia
NCT068904941 location
Natural History Study to Determine Drug Metabolism Phenotype and Appropriate Germline Source DNA in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant
NCT068562261 location